Top Page
Arovella Therapeutics Limited
(Sydney:ALA)
Arovella Therapeutics Limited (ALA) vs. iShares MSCI Australia ETF (EWA)
Arovella Therapeutics Limited Business Overview & Revenue Model
Arovella Therapeutics Limited Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.45M | 17.00K | 405.90K | 295.81K | 257.35K | 532.69K |
| Gross Profit | 3.43M | 17.00K | -3.00M | 88.75K | 34.60K | 331.72K |
| EBITDA | -6.49M | -8.83M | -10.37M | -7.87M | -4.99M | -3.40M |
| Net Income | -6.26M | -8.75M | -10.18M | -8.62M | -5.05M | -9.94M |
Balance Sheet | ||||||
| Total Assets | 12.65M | 13.28M | 5.47M | 9.21M | 10.69M | 6.71M |
| Cash, Cash Equivalents and Short-Term Investments | 11.75M | 12.71M | 5.18M | 6.07M | 6.72M | 977.47K |
| Total Debt | 0.00 | 0.00 | 0.00 | 144.80K | 79.23K | 85.46K |
| Total Liabilities | 1.11M | 2.06M | 1.69M | 1.60M | 1.71M | 2.57M |
| Stockholders Equity | 11.54M | 11.23M | 3.78M | 7.62M | 8.98M | 4.14M |
Cash Flow | ||||||
| Free Cash Flow | -6.54M | -7.04M | -6.40M | -6.83M | -4.06M | -3.27M |
| Operating Cash Flow | -6.09M | -6.91M | -6.40M | -6.27M | -3.54M | -2.88M |
| Investing Cash Flow | -453.80K | -179.34K | 95.42K | -566.00K | -514.55K | -388.42K |
| Financing Cash Flow | 13.53M | 14.61M | 5.41M | 6.19M | 9.80M | -63.94K |
Arovella Therapeutics Limited Technical Analysis
Arovella Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.41B | 0.36 | -61.88% | 2.34% | 16.99% | 1.69% | |
40 Underperform | AU$130.39M | ― | -85.35% | ― | 315.11% | 51.16% | |
| $482.57M | ― | ― | ― | ― | |||
| $25.09M | ― | -75.39% | ― | ― | ― | ||
| $228.94M | ― | -31.16% | ― | ― | ― | ||
56 Neutral | AU$37.04M | ― | -36.95% | ― | ― | 11.11% | |
54 Neutral | AU$208.49M | ― | -37.20% | ― | ― | 32.02% |
Arovella Therapeutics Limited Corporate Events
Arovella Therapeutics has secured an exclusive option from Baylor College of Medicine to license two innovative chimeric antigen receptors (CARs) aimed at solid tumors, including neuroblastoma and hepatocellular carcinoma. This strategic move could position Arovella as a leading player in the iNKT cell therapy space, enhancing its platform’s capabilities and potentially increasing its market differentiation. The option includes access to advanced manufacturing technology and genetic modifications that could improve the efficacy of Arovella’s CAR-iNKT cell platform, offering significant implications for its operational and competitive positioning in the biotechnology industry.
Arovella Therapeutics Ltd announced an investor webinar to update stakeholders on its progress and future plans, including the transition towards Phase 1 in-human trials for its iNKT cell therapy platform. This move is pivotal for Arovella as it seeks to strengthen its position in the biotechnology industry by advancing its innovative cancer treatment solutions, potentially impacting its market presence and stakeholder interests.
Arovella Therapeutics Limited announced an investor webinar to update shareholders and interested parties on its quarterly progress and future steps as it advances towards Phase 1 in-human trials. The webinar, presented by CEO Dr. Michael Baker, will provide insights into the company’s strategic direction for 2025, potentially impacting its market positioning and stakeholder interests.
Arovella Therapeutics Limited has reported significant progress in its third quarter of FY25, with a cash reserve of $23.5 million and a successful $15 million placement to fund the phase 1 trial of its lead product, ALA-101. The company has also transferred its manufacturing process into a cGMP environment and completed key IND-enabling studies, positioning itself well for upcoming clinical trials and further expansion of its iNKT cell therapy platform.
Arovella Therapeutics Limited has announced that its 2025 Extraordinary General Meeting (EGM) will be held virtually on May 8, 2025. Shareholders are encouraged to vote in advance to facilitate meeting preparations, with proxy forms due by May 6, 2025. The company is also adapting to recent changes in the Corporations Act, allowing shareholders to choose their preferred method of receiving company communications, either electronically or in hard copy, to enhance efficiency and sustainability.
Arovella Therapeutics Limited announced the cancellation of a previous proposal to issue securities under a cleansing prospectus aimed at facilitating secondary trading, as the offer closed with no shares issued. This cancellation may impact the company’s funding strategy and market positioning, potentially affecting stakeholders’ expectations regarding future capital raising activities.
Arovella Therapeutics Limited announced the cancellation of a previous securities issuance proposal. The options, initially offered under a cleansing prospectus to facilitate secondary trading, were closed without any being issued. This decision may impact the company’s financial strategy and stakeholder expectations, as the proposed securities were not issued.
Arovella Therapeutics Limited announced the cessation of 2,500,000 securities due to the expiry of options or other convertible securities without exercise or conversion. This announcement reflects a routine adjustment in the company’s issued capital, which may impact its financial structuring and investor relations.
Arovella Therapeutics Limited has applied for the quotation of 115,897,550 options, known as May Options, which were initially issued as part of a $12.5 million placement in April 2024. The company has lodged a cleansing prospectus to facilitate the secondary trading of these options, with trading expected to commence on 27 March 2025 under the ASX code ‘ALAO’. This move is part of Arovella’s strategy to enhance liquidity and market presence, potentially impacting its financial operations and stakeholder engagement.
Arovella Therapeutics Limited has announced a proposed issue of securities, with a maximum of 10 options set to expire on May 24, 2027. This move is part of a placement or other type of issue, and the securities are intended to be quoted on the Australian Securities Exchange (ASX). The proposed issue date is April 1, 2025, and this announcement could potentially impact the company’s market positioning by providing additional capital for its operations and strategic initiatives.
Arovella Therapeutics Limited has issued a prospectus for a Cleansing Offer, proposing the issuance of up to 10 new options at a price of $0.01 each. This move is intended to remove trading restrictions on options issued before the closing date, providing more flexibility in the company’s securities trading. The offer is highly speculative and is not available to the general public, with the company emphasizing the need for potential investors to conduct thorough due diligence.
Arovella Therapeutics Limited has released a report detailing the top 20 holders of its listed options, which are set to expire on May 24, 2027, with an exercise price of $0.15. The report highlights that BNP Paribas Noms Pty Ltd holds the largest share at 9.35%, followed by Netwealth Investments Limited at 4.71%. The total issued capital stands at 39,905,625, with the top 20 holders accounting for 63.06% of this total. This report provides insights into the company’s shareholder structure, which could influence investor perceptions and market dynamics.
Arovella Therapeutics Limited has announced the completion of a $15 million placement of ordinary shares, which includes attaching options on a 1-for-3 basis. The company is seeking to quote these placement attaching options, totaling 39,905,625 options set to expire on May 24, 2027. This move is expected to bolster Arovella’s financial position and potentially enhance its market presence by providing additional capital for its ongoing and future projects.
Arovella Therapeutics Limited has announced the quotation of 119,717,123 fully paid ordinary securities on the ASX, effective March 5, 2025. This move is part of previously announced transactions and signifies an expansion in the company’s market activities, potentially impacting its financial standing and investor relations positively.
Arovella Therapeutics Ltd has entered into a Sponsored Research Agreement with the University of North Carolina to enhance its research capabilities for IL-12-TM and solid tumor programs. This collaboration with Professor Gianpietro Dotti’s research group aims to strengthen Arovella’s position in the biotechnology sector by advancing its CAR-iNKT cell programs, potentially improving treatment options for solid tumors.
Arovella Therapeutics faced a setback when a private investor failed to fulfill a $15 million share subscription agreement, prompting the company to initiate a new capital raise. Despite the challenges, Arovella successfully secured $15 million from new investors, bolstering its cash position and enabling the continuation of its clinical trial for ALA-101. The funds will also support the development of other programs, reinforcing Arovella’s commitment to advancing its therapeutic pipeline.
Arovella Therapeutics Limited reported an 82% increase in revenue to $3.68 million for the half-year ended December 2024, while its loss from continuing operations decreased by 63% to $1.46 million. Despite the financial improvements, no dividends were declared, indicating a focus on reinvestment or strategic growth within the company.
Arovella Therapeutics Limited has announced a proposed issue of securities, with a maximum of 100 ordinary fully paid securities to be issued. This move, set for March 31, 2025, aims to bolster the company’s financial position and potentially enhance its market presence, signaling a strategic step in its operational growth.
Arovella Therapeutics Limited announced a proposed issue of securities, including 119,717,123 ordinary fully paid shares and 39,905,699 options expiring in May 2027. This move is aimed at raising capital to support the company’s ongoing projects and strategic initiatives, potentially enhancing its market position and providing value to stakeholders.
Arovella Therapeutics Limited announced the cancellation of a previously proposed securities issue due to an investor defaulting on a contractual settlement for a AUD 15 million subscription. This decision may impact the company’s funding strategy and market positioning, highlighting the challenges of securing investment commitments in the biotech sector.
Arovella Therapeutics Limited has issued a prospectus for an offer of up to 100 new shares at $0.125 per share and nearly 40 million placement options. This move is designed to remove trading restrictions on shares issued before the closing date, reflecting the company’s strategic efforts to enhance its market liquidity and investor appeal. The offer is considered highly speculative, and potential investors are advised to conduct thorough due diligence.
Arovella Therapeutics Limited has successfully secured approximately $15 million through a new placement of shares, allowing the company to complete phase 1 enrolment and generate initial clinical data for its lead product, ALA-101, targeting CD19-positive blood cancers. This funding will also support the expansion of Arovella’s solid tumor programs, positioning the company to achieve critical milestones such as securing IND approval from the US FDA and obtaining proof-of-concept data, thereby enhancing its market position and creating value for stakeholders.
Arovella Therapeutics Limited, a company trading on the Australian Securities Exchange, has requested a voluntary suspension of its securities. This suspension, effective immediately, is to allow the company to manage its disclosure obligations related to an impending capital raising announcement. The suspension will remain until either the market announcement is made or normal trading resumes on February 17, 2025. This move is likely to impact stakeholders by temporarily halting trading activities for Arovella’s securities, indicating significant forthcoming business developments.
Arovella Therapeutics Limited has requested a trading halt on its securities as it prepares to release a significant market announcement concerning a capital raising placement. This move is aimed at managing its disclosure obligations, with the expectation of releasing the announcement before trading resumes on February 10, 2025.